{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-038533","form_type":"8-K","ticker":"MRKR","cik":"0001094038","company_name":"Marker Therapeutics, Inc.","filed_at":"2024-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.347006+00:00","generated_at":"2026-06-04T07:35:17.796311+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Marker Therapeutics reports FY 2023 net loss of $8.2M, down from $29.9M; cash runway into Q4 2025","bullets":["Net loss narrowed to $8.2M in FY 2023 from $29.9M in FY 2022; R&D spend cut to $10.4M from $12.0M.","Cash and equivalents $15.1M at Dec 31, 2023; company expects funding into Q4 2025 via grant drawdowns.","First lymphoma patient treated with MT-601 achieved sustained complete response >6 months after CAR T relapse.","Completed $19M asset sale to Cell Ready reducing annual overhead ~$11M; secured $2M NIH grant for AML program.","Appointed Juan Vera as CEO/Principal Financial Officer and Monic Stuart as CMO."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-038533","json":"https://secwatch.observer/filing/0001104659-24-038533.json","markdown":"https://secwatch.observer/filing/0001104659-24-038533.md","text":"https://secwatch.observer/filing/0001104659-24-038533.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1094038/000110465924038533/0001104659-24-038533-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1094038/000110465924038533/tm249709d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T07:35:17.796311+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f48c309c85f5bbe0a77bd33c828bf123ae522043","claim":"Marker Therapeutics, Inc. reported financial results for the fiscal year ended December 31, 2023.","evidence_excerpt":"On March 25, 2024, Marker Therapeutics, Inc. (the “ Company ”) reported financial results for the fiscal year ended December 31, 2023 and other recent corporate updates.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1094038/000110465924038533/0001104659-24-038533-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}